BRAINSTORM CELL THERAPEUTICS (BCLI) Stock Price, Quote, News and Overview

What is the stock price of BRAINSTORM CELL THERAPEUTICS today?

The current stock price of BCLI is 0.876 USD. The price increased by 10.19% in the last trading session.

What is the ticker symbol for BRAINSTORM CELL THERAPEUTICS stock?

The exchange symbol of BRAINSTORM CELL THERAPEUTICS is BCLI and it is listed on the Nasdaq exchange.

On which exchange is BCLI stock listed?

BCLI stock is listed on the Nasdaq exchange.

What is the price forecast or stock price prediction for BRAINSTORM CELL THERAPEUTICS stock?

7 analysts have analysed BCLI and the average price target is 14.11 USD. This implies a price increase of 1511.12% is expected in the next year compared to the current price of 0.876. Check the BRAINSTORM CELL THERAPEUTICS stock analysts ratings, price target forecast and up-and down grades for more detailed information.

What is BRAINSTORM CELL THERAPEUTICS worth?

BRAINSTORM CELL THERAPEUTICS (BCLI) has a market capitalization of 5.71M USD. This makes BCLI a Nano Cap stock.

How many employees does BRAINSTORM CELL THERAPEUTICS have?

BRAINSTORM CELL THERAPEUTICS (BCLI) currently has 29 employees.

What are the support and resistance levels for BRAINSTORM CELL THERAPEUTICS (BCLI) stock?

BRAINSTORM CELL THERAPEUTICS (BCLI) has a resistance level at 1.27. Check the full technical report for a detailed analysis of BCLI support and resistance levels.

Should I buy BRAINSTORM CELL THERAPEUTICS (BCLI) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:

• The Technical Analysis (TA) tab contains a technical analysis of BCLI, looking at technical quality and support and resistance levels
• The Fundamental Analysis (FA) tab contains a fundamental analysis of BCLI, evaluating the profitability, health, valuation and growth aspects
• BRAINSTORM CELL THERAPEUTICS (BCLI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
• BRAINSTORM CELL THERAPEUTICS (BCLI) Sales and EPS estimates to see what analysts future expectations are.
• BRAINSTORM CELL THERAPEUTICS (BCLI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
• BRAINSTORM CELL THERAPEUTICS (BCLI) Insider and Institutional Ownership to learn about the owners and their transactions.
• BRAINSTORM CELL THERAPEUTICS (BCLI) Stock Chart to make your own analysis
• BRAINSTORM CELL THERAPEUTICS (BCLI) Latest news and press-releases to stay up to date.

Does BRAINSTORM CELL THERAPEUTICS (BCLI) stock pay dividends?

BCLI does not pay a dividend.

When does BRAINSTORM CELL THERAPEUTICS (BCLI) report earnings?

BRAINSTORM CELL THERAPEUTICS (BCLI) will report earnings on 2025-05-12.

What is the Price/Earnings (PE) ratio of BRAINSTORM CELL THERAPEUTICS (BCLI)?

BRAINSTORM CELL THERAPEUTICS (BCLI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.37).

What is the Short Interest ratio of BRAINSTORM CELL THERAPEUTICS (BCLI) stock?

The outstanding short interest for BRAINSTORM CELL THERAPEUTICS (BCLI) is 2.41% of its float. Check the ownership tab for more information on the BCLI short interest.

ChartMill assigns a fundamental rating of 1 / 10 to BCLI. Both the profitability and financial health of BCLI have multiple concerns.

Over the last trailing twelve months BCLI reported a non-GAAP Earnings per Share(EPS) of -2.37. The EPS decreased by -22.39% compared to the year before.

ChartMill assigns a Buy % Consensus number of 83% to BCLI. The Buy consensus is the average rating of analysts ratings from 7 analysts.